Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS

The ERA Chair for Translational Genomics and Personalized Medicine

Project description

Innovative translational genomic research at the University of Tartu

Translational genomics plays a vital role in enhancing our comprehension of human biology and facilitating the discovery of novel treatments and disease prevention strategies. The EU-funded TransGeno project aims to establish the Centre of Translational Genomics as a permanent and sustainable unit at the University of Tartu (UT). The project will recruit a distinguished researcher as the ERA Chair of Translational Genomics at UT. The primary objective of the ERA Chair will be to assemble a highly skilled team dedicated to conducting innovative translational genomic research. They will be responsible for developing and implementing the first-ever PhD curriculum on Translational Genomics in eastern Europe. The ERA Chair will collaborate with other departments within UT, fostering partnerships with leading institutions worldwide.

Objective

TransGeno seeks to hire a top researcher as ERA Chair of Translational Genomics at the University of Tartu (UT). In addition to assembling a highly skilled team to engage in cutting edge translational genomic research, the ERA Chair will promote change throughout the university in several ways:

• Establishing the Centre of Translational Genomics as a permanent and sustainable unit within UT
• Implementing a PhD curriculum on Translational Genomics - the first one of its kind in Eastern Europe.
• Coordinate with other departments to make more efficient and effective use of UT’s research capacity.
• Forge partnerships with leading institutions to attract top students and researchers from around the world as well as additional funding.

The ERA Chair will also engage with various stakeholders, including:

• Health sector business clusters to explore ways to exploit research results
• Medical doctors to educate them on how one form of TG information, clinical genomic data, can be useful in everyday practice.
• Youth and the general public to popularize genomics and spur young people into STEM sciences.
• International researchers by sharing research data and results in as open way as possible, either at ‘green’ or ‘gold’ open access standards.

TG applies innovations from genomics to diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases. It enables scientists to understand the genetic components of disease, which could lead to a shift from treatment based on symptoms to treatment based on underlying causes of disease. As Europe’s population ages and people must live with chronic diseases for longer this becomes more important. Advances in TG research could lead to early treatment of diseases and in the most ideal scenarios, enable doctors to treat patients before the onset of disease. TransGeno will increase research excellence in Estonia and enable UT to become a world leader in these efforts.

Call for proposal

H2020-WIDESPREAD-2014-2015

See other projects for this call

Sub call

H2020-WIDESPREAD-2014-2

Coordinator

TARTU ULIKOOL
Net EU contribution
€ 2 409 700,00
Address
ULIKOOLI 18
51005 Tartu
Estonia

See on map

Region
Eesti Eesti Lõuna-Eesti
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 677 500,00